Daily Expert News
No Result
View All Result
Tuesday, June 28, 2022
  • Home
  • World
  • Economy
  • Business
  • Markets
  • Arts & Culture
  • Education & Career
  • India
  • Politics
  • Top Stories
Daily Expert News
  • Home
  • World
  • Economy
  • Business
  • Markets
  • Arts & Culture
  • Education & Career
  • India
  • Politics
  • Top Stories
No Result
View All Result
Daily Expert News
No Result
View All Result
  • Home
  • World
  • Economy
  • Business
  • Markets
  • Arts & Culture
  • Education & Career
  • India
  • Politics
  • Top Stories
Home Uncategorized

Newly identified drug could help effectively treat COVID-19 pneumonia: lancet study

by Nick Erickson
December 18, 2021
in Uncategorized
129 4
0
NDTV News
152
SHARES
1.9k
VIEWS
Share on FacebookShare on Twitter
ADVERTISEMENT


A newly identified drug could be used to effectively treat patients with COVID-19 pneumonia

London:

According to a study published in the journal The Lancet Respiratory Medicine, a newly identified drug could be used to effectively treat some patients hospitalized with COVID-19 pneumonia.

The team, which includes researchers from the University of Birmingham and the University of Oxford, UK, tested namilumab – an antibody already in late-stage trials for the treatment of rheumatoid arthritis – in patients hospitalized with COVID-19. 19 pneumonia.

The patients received ‘regular’ care and also had high levels in their blood of an inflammatory marker known as C-reactive protein (CRP).

CRP levels rise when there is inflammation in the body, and elevated levels of CRP appear to be a potential early marker to predict the risk of COVID-19 severity, the researchers said.

“Our study has provided important proof-of-concept evidence that namilumab reduces inflammation in hospitalized patients with COVID-19 pneumonia,” said Ben Fisher, co-principal investigator of the study at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust ( UHB).

“However, our sample size is too small for a definitive assessment of clinical outcomes and further studies are needed, as well as to better understand the population that could benefit most,” Ben Fisher said.

Namilumab targets a ‘cytokine’ that is naturally secreted by immune cells in the body, but in uncontrolled levels it is believed to be a major cause of the excessive and dangerous pneumonia seen in COVID-19 patients.

The trial, conducted between June 2020 and February 2021, involved patients over 16 years of age with COVID-19 pneumonia who were treated either in a ward or intensive care unit (ICU) at nine hospitals in the UK.

The study involved 54 patients who received ‘ordinary care’ – treatment with steroids and oxygen or ventilation – and 57 patients who received usual care, as well as a single 150 mg intravenous dose of namilumab.

In addition to COVID-19 pneumonia, all study participants had CRP levels greater than 40 mg/L.

The researchers compared the chance of a reduction in CRP levels in patients.

Compared with usual care alone, the researchers found there was a 97 percent chance that CRP was reduced over time in those who received namilumab compared with usual care alone.

The patients were monitored, and after 28 days, the study also showed that there were fewer deaths and more hospital or ICU discharges in those who received namilumab compared to those who received usual care alone.

On Day 28, 78 percent of patients who received namilumab were discharged from the hospital or ICU, compared with 61 percent who received usual care.

According to the researchers, 11 percent of the namilumab group were still in the hospital on day 28, compared to 20 percent in the usual care group. Of those in the namilumab group, 11 percent of patients died, compared with 19 percent who died on day 28 in the usual care group, they said.

The team calculated the differences between the two groups in the overall likelihood of being discharged from the ICU or ward after 28 days. Of those on a ward, the chance of discharge on Day 28 was 64 percent in the usual care group, compared to 77 percent in the namilumab cohort.

Of those in the ICU, the chance of discharge at Day 28 was 47 percent in the usual care group, according to the study, compared with 66 percent in the namilumab cohort.

The researchers noted that the study results may not be generalized to hospitalized patients without evidence of pneumonia or elevated CRP or patients who do not require hospitalization.

It is therefore important that namilumab now be prioritized for further COVID-19 research in a much larger phase 3 clinical trial, she added.

(Except for the headline, this story has not been edited by DailyExpertNews staff and has been published from a syndicated feed.)

ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
Tags: Covid19DailyExpertNewsdrugeffectivelyidentifiedlancetnewlypneumoniastudytreat

Get real time update about this post categories directly on your device, subscribe now.

Unsubscribe
ADVERTISEMENT

Related Posts

Young Jugraj Singh beats hat-trick as India beats South Africa 10-2 in FIH Pro League Hockey | Hockey News
Uncategorized

Harmanpreet Singh scores four goals in India’s 10-2 smashing of South Africa in FIH Pro League Hockey | Hockey News

February 13, 2022
Review: An audition season begins at the Philharmonic
Uncategorized

Review: An audition season begins at the Philharmonic

February 13, 2022
Good way to good taste
Uncategorized

Good way to good taste

February 13, 2022
Good way to good taste
Uncategorized

Good way to good taste

February 13, 2022
What to cook this week
Uncategorized

What to cook this week

February 13, 2022
Sigal Barsade, 56, dies; Argued it's okay to show emotions at work
Uncategorized

Sigal Barsade, 56, dies; Argued it’s okay to show emotions at work

February 13, 2022
  • Trending
  • Comments
  • Latest
This optical illusion has a revelation about your brain and eyes

This optical illusion has a revelation about your brain and eyes

June 6, 2022
NDTV Coronavirus

Viral video: Chinese woman pinned down, Covid test carried out by force

May 5, 2022
Hundreds In Sarees At UK

Hundreds of sarees at Britain’s Royal Ascot Horse Race to help Indian weavers

June 16, 2022
Sabrina's parents love her. But the meltdowns are too many.

Sabrina’s parents love her. But the meltdowns are too many.

June 1, 2022

Hello world!

0
NDTV News

IT startup Fareye aims to change Unicorn within a year, founder says

0
How did Stephanie Murphy, a holdout on Biden's agenda, help save it?

How did Stephanie Murphy, a holdout on Biden’s agenda, help save it?

0
How did Stephanie Murphy, a holdout on Biden's agenda, help save it?

How did Stephanie Murphy, a holdout on Biden’s agenda, help save it?

0
A couple's long journey in the anti-abortion movement

A couple’s long journey in the anti-abortion movement

June 27, 2022
Lithuania blames Russia for cyber-attacks, citing threats over cargo restrictions.

Lithuania blames Russia for cyber-attacks, citing threats over cargo restrictions.

June 27, 2022
They found two new craters on the moon and uncovered a new mystery

They found two new craters on the moon and uncovered a new mystery

June 27, 2022
NATO

NATO’s encroachment on Crimea could lead to World War III: ex-Russian president

June 27, 2022
ADVERTISEMENT

Recent News

A couple's long journey in the anti-abortion movement

A couple’s long journey in the anti-abortion movement

June 27, 2022
Lithuania blames Russia for cyber-attacks, citing threats over cargo restrictions.

Lithuania blames Russia for cyber-attacks, citing threats over cargo restrictions.

June 27, 2022

Categories

  • Africa
  • Americas
  • art-design
  • Arts
  • Asia Pacific
  • Astrology News
  • books
  • Books News
  • Business
  • Cricket
  • Cryptocurrency
  • Dance
  • Dining and Wine
  • Economy
  • Education & Career
  • Europe
  • Fashion
  • Food
  • Football
  • Gadget
  • Gaming
  • Golf
  • Health
  • Hot News
  • India
  • Indians Abroad
  • Lifestyle
  • Markets
  • Middle East
  • Most Shared
  • Motorsport
  • Movie
  • Music
  • New York
  • Opinion
  • Politics
  • press release
  • Real Estate
  • Review
  • Science & Space
  • Sports
  • Sunday Book Review
  • Tax News
  • Technology
  • Television
  • Tennis
  • Theater
  • Top Movie Reviews
  • Top Stories
  • Travel
  • Uncategorized
  • Web Series
  • World

Site Navigation

  • Home
  • Advertisement
  • Contact Us
  • Privacy & Policy
  • Other Links

We bring you the Breaking News,Latest Stories,World News, Business News, Political News, Technology News, Science News, Entertainment News, Sports News, Opinion News and much more from all over the world

©Copyright DailyExpertNews 2022

No Result
View All Result
  • Contact Us
  • Home
  • Top Stories
  • World
  • Economy
  • Business
  • Opinion
  • Markets
  • India
  • Education & Career
  • Arts
  • Advertisement
  • Tax News
  • Markets

©Copyright DailyExpertNews 2022

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.